Fermenta Biotech Limited

CIN: L99999MH1951PLC008485
Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road,
Majiwade, Thane (W) - 400 610, Maharashtra, India.
Tel. : +91-22-6798 0888 Email : info@fermentabiotech.com,
Website. : www.fermentabiotech.com

August 11, 2026

BSE Limited	**National Stock Exchange of India Limited**
Phiroze Jeejeebhoy Towers,	Exchange Plaza, Plot No. C/1,
Dalal Street, Fort,	G Block, Bandra - Kurla Complex,
Mumbai – 400 001	Bandra (East), Mumbai 400 051
Scrip Code: **506414**	Trading Symbol: **FERMENTA**

Dear Sir,

Sub: Press Release

Please find enclosed herewith a 'Press Release' issued by the Company regarding unaudited financial results of Q1FY27.

Kindly take the above on record.

Thanking you,

Yours faithfully,
For **Fermenta Biotech Limited**

VARADVINAYAK VIJAY KHAMBETE
Digitally signed by VARADVINAYAK VIJAY KHAMBETE
Date: 2026.08.11 13:29:07 +05'30'

Varadvinayak Khambete
Company Secretary & Head - Legal
Membership No. A33861

Encl: As above

Press Release

Fermenta Q1FY27 Consolidated Revenue INR 126.2 crore; flat QoQ and down 13% YoY

BSE: 506414	NSE: FERMENTA	Bloomberg: FERMENTA:IN	Reuters: FERM.BO

- Consolidated Q1FY27 EBITDA (excluding real estate) INR 22.3 crore, down 37% YoY and 10% QoQ
- Revenue near flat QoQ, with human nutrition volumes up 18% QoQ
- April–June 2025 carried INR 2.7 crore of non-recurring insurance income and INR 1.6 crore of real estate value unlocking; neither recurs in the current quarter
- India rose to 47% of consolidated revenue in April–June 2026 from 35% a year earlier, with Other APIs and Intermediates up 18% YoY and Green Chemistry Solutions / Enzymes up 15% YoY
- “Human nutrition volumes rose sequentially, India strengthened as a market, and the FSSAI approval for VITADEE Green® opens a new one”: Prashant Nagre – Managing Director

Mumbai, 11 August 2026: Fermenta Biotech Limited, one of the world’s largest manufacturers of Vitamin D3 API, and a growing portfolio of premium-grade nutritional ingredients, green chemistry, APIs and intermediates, today announced that its consolidated revenue (other than from real estate) for the quarter ended 30 June 2026 was INR 124.3 crore, down 12% YoY and flat QoQ; EBITDA (other than from real estate) for the quarter ended 30 June 2026 was INR 22.3 crore, down 37% YoY and 10% QoQ. The year-on-year comparison is set against an exceptionally strong April–June 2025 quarter. Within the current quarter, human nutrition volumes rose 18% sequentially, the domestic market strengthened materially, and every business other than Vitamin D3 – Animal Nutrition grew year-on-year.

On the consolidated basis Q1FY27 revenue (including real estate) was INR 126.2 crore (down 13% YoY and flat QoQ), EBITDA INR 22.4 crore (down 39% YoY and 11% QoQ) and Profit after Tax INR 9.5 crore (down 56% YoY and 49% QoQ). The year-on-year decline in profit after tax is accounted for by three identifiable items in the April–June 2025 base quarter rather than by the core business: a 40% fall in Vitamin D3 – Animal Nutrition realisations; Other Income of INR 8.77 crore against INR 4.37 crore in the current quarter, the base having carried a non-recurring insurance claim of INR 2.7 crore; and INR 1.6 crore of real estate value-unlocking income, against nil in the current quarter. Unless stated otherwise, all figures in this release are for the April–June 2026 quarter (Q1FY27); year-on-year comparisons are against April–June 2025 (Q1FY26) and quarter-on-quarter comparisons against January–March 2026 (Q4FY26).

Key financials (consolidated) without real estate

	Q1FY27
Revenue	INR 124.3 crore (down 12% YoY, flat QoQ)
EBITDA	INR 22.3 crore (down 37% YoY, down 10% QoQ)

Key financials (consolidated) with real estate

	Q1FY27
Revenue	INR 126.2 crore (down 13% YoY, flat QoQ)
EBITDA	INR 22.4 crore (down 39% YoY, down 11% QoQ)
Profit after tax	INR 9.5 crore (down 56% YoY, down 49% QoQ)
EPS (diluted)	Rs. 3.34

Revenue mix (consolidated)

	Q1FY27 (INR crore)	Q4FY26 (INR crore)	QoQ change (%)	Q1FY26 (INR crore)	YoY change (%)
Nutrition Business					
Vitamin D3 – Human Nutrition	76.5	61.7	+24%	84.7	-10%
Vitamin D3 – Animal Nutrition	12.6	22.9	-45%	21.4	-41%
Others	11.0	9.5	+16%	8.5	+28%
Other Business					
Other APIs and Intermediates	11.6	18.1	-36%	9.8	+18%

Green Chemistry Solutions / Enzymes	2.3	6.9	−67%	2.0	+15%
Environmental Solutions	6.0	0.8	+619%	6.6	−8%
Other Income	6.2	6.7	−8%	10.4	−41%
Value Unlocking					
Real Estate	0	0	−100%	1.6	−100%

Geographical Revenue Mix (consolidated) excluding real estate value unlocking

	Q1FY27	Q4FY26	Change (%)	Q1FY26	Change (%)
India	47%	38%	+9%	35%	+12%
Europe	23%	22%	+1%	33%	−10%
North America	10%	15%	−5%	13%	−3%
Others	20%	25%	−5%	19%	+1%

Performance highlights

- Human nutrition segment volumes grew 18% QoQ and were down 21% YoY, with revenue of INR 76.5 crore keeping the segment at 61% of consolidated revenue.
- Animal nutrition segment volumes were down 52% QoQ and 20% YoY, with average realisation down 40% YoY.
- Green Chemistry Solutions / Enzymes revenue grew 15% YoY to INR 2.3 crore, as customer acquisitions made over the past year began converting into repeat volumes. Other APIs and Intermediates grew 18% YoY to INR 11.6 crore and the Others line within nutrition grew 28% YoY to INR 11.0 crore.
- Other Income was INR 4.37 crore against INR 8.77 crore a year earlier, down 50% YoY. The base quarter included a non-recurring insurance claim of INR 2.7 crore together with higher foreign exchange gains. Other Income sits above EBITDA and is therefore already reflected in the EBITDA movement reported above.

- Our German subsidiary's Q1FY27 revenue was INR 6.6 crore, down 58% YoY and 41% QoQ, with EBITDA at INR 0.8 crore loss, down INR 5.8 crore YoY and INR 0.9 crore QoQ. Our US trading business subsidiary's Q1FY27 revenue was INR 10.5 crore, down 38% YoY and up 36% QoQ, with EBITDA at INR 0.7 crore loss, down INR 0.3 crore YoY and up INR 0.1 crore QoQ. Our Environment subsidiary's Q1FY27 revenue was INR 6.1 crore, with EBITDA at INR 2.9 crore loss, down INR 1.1 crore QoQ.
- Slow-moving semi-finished inventory used in animal feed production continued to be consumed during the quarter, allowing a further INR 2.0 crore of the write-down previously taken against it to be written back. The write-back is non-cash, reduces the cost of materials consumed, and is included in the reported EBITDA of INR 22.4 crore.
- The one-time exceptional employee-benefit charge of INR 2.19 crore arising from the four new Labour Codes notified by the Government of India on 21 November 2025 was recognised in FY26. The Codes have been implemented in full and the charge does not recur in the April–June 2026 quarter.
- The INR 9.07 crore recovery of amounts previously provided against investment, expense recoverables and trade receivables was reversed and recorded as an exceptional item in FY26. It does not form part of the April–June 2026 result, and the current quarter carries no exceptional items.
- During the quarter, the Company embarked on a nationwide public awareness campaign on Vitamin D deficiency, opening with full-page executions in The Times of India on 14 May 2026 and Mumbai Mirror on 15 May 2026. The Company plans to build on this campaign further during FY27.
- Post quarter-end, VITADEE Green®, Fermenta's plant-source Vitamin D3, received FSSAI approval on 06 July 2026 for use as an ingredient in health supplements, nutraceuticals, food products and large scale food fortification, opening India's large vegetarian consumer base to a domestically manufactured, patent-backed Vitamin D3.
- In June 2026, in the Company's 75th year, Fermenta was ranked 7th nationwide in the Top 50 category of India's Great Mid-size Workplaces™ 2026 by Great Place To Work®, from a field of more than 2,000 participating organisations.

Commenting on the results, Prashant Nagre, Managing Director, said:

"This was a quarter of building rather than harvesting. The year-on-year arithmetic sits against an exceptionally strong April–June 2025 base and does not describe the direction of the business. Human nutrition volumes rose 18% over the preceding quarter, India moved to 47% of consolidated revenue from 35% a year ago, and every business other than animal nutrition grew.

Other APIs and Intermediates grew 18% year-on-year. Green Chemistry Solutions and Enzymes 15%, and the Others line within nutrition 28%. These are smaller businesses today, but they are growing on their own customer wins. Animal nutrition remains the soft spot, with realisations down 40%, and we have chosen volume discipline over chasing a weak price.

Two milestones since the quarter closed give us particular confidence. In July, VITADEE Green® received FSSAI approval for use in health supplements, nutraceuticals, food products and food fortification, taking the plant-source Vitamin D3 developed and manufactured in India directly to Indian formulators. And in June, in our 75th year, Fermenta was ranked 7th nationwide among India's Great Mid-size Workplaces™ 2026. With commercial-scale plant-based Vitamin D3 capacity coming up at Dahej, we remain focused on scaling our core human nutrition business while broadening the earnings base."

About

Fermenta Biotech Limited (www.fermentabiotech.com) is one of the world's largest manufacturers of Vitamin D3 API, with a growing portfolio of premium-grade nutritional ingredients, green chemistry solutions, APIs and intermediates. Manufacturing facilities at Kullu (Himachal Pradesh), Dahej (Gujarat) and Tirupati (Andhra Pradesh), supported by the R&D Excellence Centre at Thane, serve over 400 customers in more than 60 countries meeting IP, USP, Ph. Eur. and FCC standards. Environmental solutions are delivered through the wholly owned subsidiary Fermenta Environment Solutions Private Limited. The Company's two flagship introductions, VITADEE Green® plant-source Vitamin D3 and the Vitamin D3 100 SD premix, are supported by a granted Indian process patent, an EDQM Certificate of Suitability and commercial-scale capacity being established at Dahej.

Disclaimer

--ends